Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 2
1961 6
1962 3
1963 4
1964 4
1965 7
1966 4
1967 3
1968 5
1969 6
1970 5
1971 3
1972 8
1973 4
1974 7
1975 12
1976 13
1977 8
1978 9
1979 3
1980 6
1981 12
1982 8
1983 14
1984 14
1985 13
1986 6
1987 19
1988 26
1989 18
1990 21
1991 21
1992 21
1993 39
1994 36
1995 50
1996 43
1997 55
1998 50
1999 50
2000 65
2001 46
2002 65
2003 66
2004 38
2005 46
2006 32
2007 36
2008 38
2009 48
2010 51
2011 62
2012 59
2013 56
2014 65
2015 55
2016 61
2017 63
2018 46
2019 49
2020 58
2021 64
2022 74
2023 59
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

1,812 results

Results by year

Filters applied: . Clear all
Page 1
iPLAT1: the first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study.
Sugimoto N, Kanda J, Nakamura S, Kitano T, Hishizawa M, Kondo T, Shimizu S, Shigemasa A, Hirai H, Arai Y, Minami M, Tada H, Momose D, Koh KR, Nogawa M, Watanabe N, Okamoto S, Handa M, Sawaguchi A, Matsuyama N, Tanaka M, Hayashi T, Fuchizaki A, Tani Y, Takaori-Kondo A, Eto K. Sugimoto N, et al. Among authors: hirai h. Blood. 2022 Dec 1;140(22):2398-2402. doi: 10.1182/blood.2022017296. Blood. 2022. PMID: 36112961 Free article. Clinical Trial. No abstract available.
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N. Goyal L, et al. Among authors: hirai h. Cancer Discov. 2019 Aug;9(8):1064-1079. doi: 10.1158/2159-8290.CD-19-0182. Epub 2019 May 20. Cancer Discov. 2019. PMID: 31109923 Free PMC article.
Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.
Takahashi H, Tada Y, Saotome T, Akazawa K, Ojiri H, Fushimi C, Masubuchi T, Matsuki T, Tani K, Osamura RY, Hirai H, Yamada S, Kawakita D, Miura K, Kamata SE, Nagao T. Takahashi H, et al. Among authors: hirai h. J Clin Oncol. 2019 Jan 10;37(2):125-134. doi: 10.1200/JCO.18.00545. Epub 2018 Nov 19. J Clin Oncol. 2019. PMID: 30452336 Clinical Trial.
1,812 results